Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism

BACKGROUND: Congenital hyperinsulinism (CHI) is a rare and life-threatening genetic disorder. Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide. However, the safety and efficacy of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Endocrinol
Egile Nagusiak: Hashemian, Somayyeh, Jafarzadeh Esfehani, Reza, Karimdadi, Siroos, Vakili, Rahim, Zamanfar, Daniel, Sahebkar, Amirhossein
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2020
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396056/
https://ncbi.nlm.nih.gov/pubmed/32774365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7250406
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak